文献速递免疫规划妇幼与学校卫生

瑞典斯德哥尔摩县HBsAg阳性母亲所生婴儿疫苗接种规划的长期随访

Long-term follow-up of a vaccination program for infants born to HBsAg-positive mothers in Stockholm County, Sweden.
PubMed 文献 · Vaccine · 2019-11-15

研究随访HBsAg阳性母亲所生婴儿的长期乙肝疫苗抗体应答:出生及1月龄各接种1剂单价乙肝疫苗,3、5、12月龄接种含乙肝成分的六价疫苗,13月龄时保护性抗-HBs比例很高;8-12岁时68名儿童中56名(82%)抗-HBs达保护水平,2名有抗-HBc血清转换迹象但无临床病史,无人存在持续感染;少量亚组加强1剂后抗-HBs从低于10 IU/L升至保护水平。

要点

  • 8-12岁时68名儿童中56名(82%)抗-HBs达保护水平,无人存在持续感染。
  • 2名儿童有抗-HBc血清转换迹象但无任何临床疾病史。
  • 少量亚组加强1剂后抗-HBs从低于10 IU/L升至保护性免疫水平。

核心结论

  • 作者认为该疫苗接种策略在生命第一个十年内可有效避免慢性感染并维持良好的血清学应答。

研究设计与样本

  • 对HBsAg阳性母亲所生婴儿疫苗接种规划进行长期随访,出生及1月龄各接种1剂单价乙肝疫苗,3、5、12月龄分别接种含乙肝成分的六价疫苗。
  • 8-12岁时共检测68名儿童,并对少量亚组在加强1剂后复测。

主要发现

  • 13月龄时保护性抗-HBs水平比例很高。
  • 8-12岁时68名儿童中56名(82%)抗-HBs达保护水平。
  • 2名儿童有抗-HBc血清转换迹象但无任何临床疾病史,无人存在持续感染。
  • 少量亚组加强1剂后,抗-HBs从低于10 IU/L升至保护性免疫水平。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

We investigated the long-term antibody response to hepatitis B virus (HBV) vaccination in babies born to chronically infected mothers. They received one dose of monovalent HBV vaccination at birth and one month of age, followed by 3 doses of hexavalent vaccine including an HBV component at ages 3, 5, and 12 months, respectively, with a very high percentage of protective anti-HBs levels at 13 months. At the age of 8-12 years, 56 out of 68 children (82%) had protective levels of anti-HBs, two had signs of anti-HBc seroconversion without any history of clinical disease and none had ongoing infection. A small subgroup was retested after one booster dose, in all resulting in increase in anti-HBs from below 10 IU/L to levels corresponding to protective immunity. We conclude that this vaccination strategy is effective throughout the first decade of life in avoiding chronic infection and in maintaining a good serological response.

来源:Vaccine,查看原文。版权归原作者所有。

引用

  1. Insulander M, Lindh G, Stenkvist J, et al. Long-term follow-up of a vaccination program for infants born to HBsAg-positive mothers in Stockholm County, Sweden. Vaccine. 2019. PMID: 31740095. doi:10.1016/j.vaccine.2019.10.100

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。